|

Allogenic CD19 CAR-γδT cell Clinical Trials

2 actively recruiting trials

Pipeline

Phase 1/2: 2

Top Sponsors

  • Chinese PLA General Hospital2

Indications

  • Cancer2
  • Non-hodgkin Lymphoma,B Cell1
  • Non-Hodgkin's Lymphoma1

Other2 trials

Allogenic CD19-targeting CAR-γδT Cell Therapy in R/R NHL
Phase 1/2
Novel Allogenic CD19-targeting CAR-γδT Cell Therapy (QH103E) in r/r NHL
Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.